New injection aims to lower dangerous fat levels in blood

NCT ID NCT07140809

Recruiting now Disease control Sponsor: Shanghai JMT-Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new injection called JMT202 in 48 Chinese adults with very high triglycerides (a type of fat in the blood). The goal is to see if it is safe and can lower triglyceride levels. Participants will receive either the drug or a placebo over several doses, and researchers will monitor for side effects and changes in lab results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JMT202 injection
What this could lead to: If successful, this could lead to a new treatment option for people with very high triglycerides, potentially reducing their risk of heart disease and pancreatitis.
What could go wrong: This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTRIGLYCERIDEMIA

Contacts and locations

Locations

The First Hospital of Peking University
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.